Recent blog posts
NCT07587840 tanCART-19/22 cells Follicular Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07587840 tanCART-19/22 cells Follicular Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07587840 clinical trial report covering tanCART-19/22 cells, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07587801 Influenza Vaccine, Adjuvanted(Seqirus GmbH) Hemodialysis complication Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07587801 Influenza Vaccine, Adjuvanted(Seqirus GmbH) Hemodialysis complication Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07587801 clinical trial report covering Influenza Vaccine, Adjuvanted(Seqirus GmbH), Phase 2, endpoints, sponsor, geography, readout timing and development
Read →
NCT07586865 Gletimbetasin Anterior Wall Myocardial Infarction Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07586865 Gletimbetasin Anterior Wall Myocardial Infarction Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07586865 clinical trial report covering Gletimbetasin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07587775 Abaloparatide Osteoporotic Fractures Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07587775 Abaloparatide Osteoporotic Fractures Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07587775 clinical trial report covering Abaloparatide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07586046 Yttrium [90Y] chloride Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07586046 Yttrium [90Y] chloride Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07586046 clinical trial report covering Yttrium [90Y] chloride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07586124 Pucotenlimab Locally Advanced Head and Neck Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07586124 Pucotenlimab Locally Advanced Head and Neck Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07586124 clinical trial report covering Pucotenlimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07586202 Amivantamab-VMJM EGFR-mutated non-small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07586202 Amivantamab-VMJM EGFR-mutated non-small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07586202 clinical trial report covering Amivantamab-VMJM, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07589439 Recombinant anti-IL-4Rα nanobody(Shanghai Novamab Biopharmaceuticals) Asthma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07589439 Recombinant anti-IL-4Rα nanobody(Shanghai Novamab Biopharmaceuticals) Asthma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07589439 clinical trial report covering Recombinant anti-IL-4Rα nanobody(Shanghai Novamab Biopharmaceuticals), Phase 2, endpoints, sponsor, geography, read
Read →
ChiCTR2600124671 Recombinant Teriparatide (Salubris) Osteoporosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
ChiCTR2600124671 Recombinant Teriparatide (Salubris) Osteoporosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
ChiCTR2600124671 clinical trial report covering Recombinant Teriparatide (Salubris), Phase 2, endpoints, sponsor, geography, readout timing and development wh
Read →
NCT07589049 Pucotenlimab Recurrent Squamous Cell Carcinoma of the Head and Neck Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07589049 Pucotenlimab Recurrent Squamous Cell Carcinoma of the Head and Neck Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07589049 clinical trial report covering Pucotenlimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07589257 Recombinant oncolytic virus M1(Guangzhou Vitron) Diffuse midline glioma, point mutation K27M in histone H3 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07589257 Recombinant oncolytic virus M1(Guangzhou Vitron) Diffuse midline glioma, point mutation K27M in histone H3 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07589257 clinical trial report covering Recombinant oncolytic virus M1(Guangzhou Vitron), Phase 2, endpoints, sponsor, geography, readout timing and develo
Read →
ChiCTR2600124718 TAN-118 Colitis, Ulcerative Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
ChiCTR2600124718 TAN-118 Colitis, Ulcerative Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
ChiCTR2600124718 clinical trial report covering TAN-118, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →